Systemic delivery of glycosylated-PEG-masked oncolytic virus enhances targeting of antitumor immuno-virotherapy and modulates T and NK cell infiltration
Yuzhi Liang, Bing Wang, Qingjing Chen, Xingyue Fu, Chenwei Jiang, Zhiwen Lin, Qiuyu Zhuang, Yongyi Zeng, Xiaolong Liu, Da Zhang
Abstract
Our findings offer a widely applicable and universal strategy to enhance cancer immuno-virotherapy through systemic administration of non-genetically engineered oncolytic viruses. This approach has the potential to overcome the limitations of current immune-virotherapy strategies and may improve clinical outcomes for cancer patients.
Topics & Concepts
Oncolytic virusCancer researchTumor microenvironmentImmune systemVirotherapyImmunotherapyImmunologyVirusAntibodyMedicineBiologyVirus-based gene therapy researchCAR-T cell therapy researchHerpesvirus Infections and Treatments